Ideaya Biosciences Inc. (30J)
XSTU
Real-time Data
06:00 AM
Day's Range
33.3552 wk Range
19.80Overview - 30J - Ideaya Biosciences Inc.
Key Statistics
Valuation
Enterprise Value
2.10B
P/E (Trailing)
‪-26.67‬
PEG Ratio
‪-0.69‬
Price / Sales (TTM)
‪13.92‬
Price / Book
‪3.17‬
EV / EBITDA
‪-11.48‬
Profitability
Profit Margin
‪-74.75%‬
Operating Margin
‪-1,380.72%‬
Return on Assets
‪-11.53%‬
Return on Equity
‪-16.21%‬
Ownership
Shares Outstanding
96.27M
Float
90.63M
Held by Insiders
‪2.19%‬
Held by Institutions
‪108.17%‬
Price stats
Beta
‪-0.09‬
50-Day Avg
‪31.29‬
200-Day Avg
‪28.49‬
Dividends
Payout Ratio
‪0.00%‬
Market Cap - 30J - Ideaya Biosciences Inc.
Peers - 30J - Ideaya Biosciences Inc.
Peer Comparison
Compared with companies in Biotechnology listed on XSTU.
- 30JXSTUIdeaya Biosciences Inc.3.25BMarket Cap+33.59%52-week change-26.12P/E (Trailing)‪-74.75%‬Profit Margin
- 6IBXSTUInnovent Biologics Inc.14.71BMarket Cap+5.19%52-week change—P/E (Trailing)‪86.53%‬Profit Margin
- 4KBXSTUKrystal Biotech Inc.8.74BMarket Cap+57.88%52-week change44.81P/E (Trailing)‪54.81%‬Profit Margin
- 2X10XSTUAbivax SA ADR8.72BMarket Cap+35.02%52-week change-20.39P/E (Trailing)‪0.00%‬Profit Margin
- 19XXSTUAxsome Therapeutics, Inc.7.98BMarket Cap+43.86%52-week change-48.38P/E (Trailing)‪92.56%‬Profit Margin
- AN6XSTUAnaptysBio Inc.1.48BMarket Cap+65.30%52-week change-107.13P/E (Trailing)—Profit Margin
- BSFAXSTUAni Pharmaceuticals Inc.1.45BMarket Cap-21.26%52-week change16.28P/E (Trailing)‪11.07%‬Profit Margin
Profile Summary - 30J - Ideaya Biosciences Inc.
About
Ideaya Biosciences Inc. is a precision medicine oncology company that discovers and develops targeted therapeutics for patient populations identified through molecular diagnostics. Its pipeline features IDE196, a protein kinase C inhibitor in Phase 2/3 clinical trials for cancers with GNAQ or GNA11 mutations; IDE397,…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
